Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 4:49 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 3,262 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo first Clear all

Conditions: Post Traumatic Stress Disorder
Interventions: Intervention A Fluoxetine Hydrochloride (HCl), Intervention A Placebo; Drug
Lead sponsor: Global Coalition for Adaptive Research; Other
Eligibility: 18 Years to 65 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 9
States / cities: Miami, Florida • Atlanta, Georgia • Tripler AMC, Hawaii + 6 more

Conditions: Chronic Lymphocytic Leukemia, Non-melanoma Skin Cancer (NMSC)
Interventions: Nicotinamide, Placebo; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Cannabis Use, Healthy
Interventions: Placebo oral capsule, THC; Drug
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years to 25 Years
Enrollment: 141 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Malaria
Interventions: MAM01 1.5 mg/kg, Placebo, MAM01 5 mg/kg, MAM01 10 mg/kg, MAM01 40 mg/kg, MAM01 450 mg, Control, MAM01 600 mg, MAM01 900 mg; Biological · Other
Lead sponsor: Gates Medical Research Institute; Other
Eligibility: 18 Years to 50 Years
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Myelodysplastic Syndromes
Interventions: Deferasirox, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 11
States / cities: Anaheim, California • Greenwood Village, Colorado • Shreveport, Louisiana + 8 more

Conditions: Musculoskeletal Pain
Interventions: omega 7, Placebo; Dietary Supplement
Lead sponsor: Bastyr University; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Kenmore, Washington

Conditions: Healthy
Interventions: PF-07328948, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: COVID-19
Interventions: SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period), Placebo; Biological · Other
Lead sponsor: Novavax; Industry
Eligibility: 6 Months to 11 Years
Enrollment: 3,600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 47
States / cities: Little Rock, Arkansas • Anaheim, California • Bellflower, California + 41 more

Conditions: Hypertension
Interventions: CTX340, Placebo; Drug
Lead sponsor: CRISPR Therapeutics AG; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Port Orange, Florida

Conditions: Pulmonary Arterial Hypertension
Interventions: Treprostinil Palmitil, Placebo; Drug
Lead sponsor: Insmed Incorporated; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 21
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 16 more

Conditions: Smoking Cessation
Interventions: Varenicline Tartrate, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 1,510 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 14
States / cities: Encino, California • Newport Beach, California • Jacksonville, Florida + 10 more

Conditions: Non Small Cell Lung Cancer (NSCLC)
Interventions: Dacomitinib, Doxycycline, Probiotic, Alclometasone cream; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 236 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 79
States / cities: Duarte, California • Fullerton, California • Irvine, California + 49 more

Conditions: Catheter Occlusion, Thrombosis
Interventions: CUSA-081, Placebo, Alteplase; Drug
Lead sponsor: Chiesi Farmaceutici S.p.A.; Industry
Eligibility: 18 Years and older
Enrollment: 462 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 35
States / cities: Little Rock, Arkansas • Redlands, California • Stockton, California + 31 more

Conditions: Obsessive-Compulsive Disorder
Interventions: Sertraline, Levetiracetam, Placebo; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Post-Traumatic Stress Disorders
Interventions: individualized Transcranial Magnetic Stimulation; Device
Lead sponsor: 72nd Medical Group, Tinker Air Force Base; Federal
Eligibility: 18 Years to 55 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Parkinson Disease Psychosis
Interventions: AGB101; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 40 Years to 85 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Posttraumatic Stress Disorder
Interventions: DHEA; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Nicotine Dependence, Smoking Cessation
Interventions: EVP-6124, Placebo Capsule, NicoDerm Patch (Active), NRT Patch (Placebo), Brief Supportive and Behavioral Treatment; Drug · Behavioral
Lead sponsor: A. Eden Evins; Other
Eligibility: 18 Years to 65 Years
Enrollment: 345 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Pulmonary Hypertension
Interventions: Albuterol, Placebo; Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Alzheimer's Disease
Interventions: VI-1121, Placebo; Drug
Lead sponsor: VIVUS LLC; Industry
Eligibility: 60 Years to 85 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 11
States / cities: San Francisco, California • Santa Monica, California • Sunrise, Florida + 8 more

Conditions: Chronic Myeloproliferative Disorders, Fatigue, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: St. John's wort; Dietary Supplement
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 1
States / cities: New York, New York

Conditions: Metastatic Squamous Non-Small Cell Lung Cancer, Metastatic Nonsquamous Non-Small Cell Lung Cancer
Interventions: Retifanlimab, Placebo, Pemetrexed, Cisplatin, Carboplatin, Paclitaxel, nab-Paclitaxel; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 583 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 3
States / cities: Anaheim, California • Whittier, California • Reading, Pennsylvania

Conditions: Herpes Labialis, Cold Sore
Interventions: SADBE, Placebo; Drug · Other
Lead sponsor: Squarex, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 5
States / cities: Redwood City, California • Doral, Florida • Boston, Massachusetts + 2 more

Conditions: Cardiac Arrest, Pregnancy Related
Interventions: Electronic curriculum and instructor-led course, then placebo, Placebo, then electronic curriculum and instructor-led course; Other
Lead sponsor: UConn Health; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Farmington, Connecticut

Search by objective public record fields.

Department of Defense PTSD Adaptive Platform Trial - Intervention A - Fluoxetine

Effects of Nicotinamide in Patients With Chronic Lymphocytic Leukemia With History of Non-melanoma Skin Cancers

Reward and Drug Effects on Mood and Brain Response

Safety, Tolerability, Pharmacokinetics and Protective Efficacy of MAM01 in Healthy Adults

Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study

Omega 7 Oil and Inflammatory Biomarker Study

A First-in-human Study of Single Doses of PF-07328948 Which is Given to Healthy Adult Participants

Study to Evaluate Safety and Immunogenicity of COVID-19 Vaccine in Children 6 Months to < 12 Years

A Trial Evaluating Safety, Tolerability and Efficacy of CTX340 in Participants With Hypertension

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension

A Study To Evaluate The Efficacy And Safety Of Varenicline Compared To Placebo For Smoking Cessation Through Reduction

Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO

Efficacy and Safety of CUSA-081 in the Restoration of Central Venous Access Device (CVAD) Functionality

Augmentation Study of Levetiracetam in Obsessive Compulsive Disorder

To Evaluate the Efficacy of EEG-guided Magnetic Resonant Therapy in War Veterans With Posttraumatic Stress Disorder

Clinical Trial Evaluating the Efficacy and Safety of AGB101 for Treatment of Parkinson's Disease Related Psychosis

Neurosteroids in PTSD - Biomarkers to Therapeutics

A Safety and Cognitive Function Study of EVP-6124 Versus Placebo in Subjects With Nicotine Dependence

Effect of Inhaled Albuterol in Pulmonary Hypertension

VI-1121 for the Treatment Alzheimer's Disease

St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer

Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer

Double-blind, Vehicle-controlled Study of the Efficacy and Safety of SADBE in Subjects With Recurrent Herpes Labialis

Obstetric Life Support, a Curriculum to Effectively Resuscitate Pregnant Patients Experiencing Cardiac Arrest.